# The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia

> **NCT07287228** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 37 (estimated)

## Conditions studied

- Aplastic Anemia
- Refractory
- Relapse

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT07287228
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07287228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07287228, "The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07287228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*